

# A multicentre clinical study of the SWIRLGRAFT ePTFE vascular access graft.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON24364

### Source

NTR

### Brief title

N/A

### Health condition

Patients with chronic renal failure who require a prosthetic vascular access for haemodialysis.

## Sponsors and support

**Primary sponsor:** Veryan Medical Ltd

Mr PL Birch

Chief Executive Officer

21 Wilson Street

London EC2M 2TD, UK

Tel. +44 1428 683 351

philip.birch@veryanmed.com

**Source(s) of monetary or material Support:** n/a

## Intervention

## Outcome measures

### Primary outcome

Patency rates.

### Secondary outcome

1. Adverse events;
2. Clinical experiences.

## Study description

### Background summary

In this prospective feasibility study a new vascular access prosthesis, the SWIRLGRAFT, is tested in haemodialysis patients. Based on its helical geometry it is supposed to diminish stenosis at the venous anastomosis resulting in improved patency rates.

### Study objective

The helical geometry of this vascular access prosthesis reduces flow stagnation and low shear stress at the venous anastomosis resulting in diminished neointimal hyperplasia.

### Study design

N/A

### Intervention

Implantation of a SWIRLGRAFT vascular access graft.

This single procedure (60-90 minutes) will be implemented in all participants and the prosthesis will remain in situ.

## Contacts

### Public

University Medical Center Utrecht (UMCU),  
HP F 03.223,

P.O.Box 85500  
H.J.T.A.M. Huijbregts  
Heidelberglaan 100  
Utrecht 3508 GA  
The Netherlands  
+31 (0)30 2507379

**Scientific**

University Medical Center Utrecht (UMCU),  
HP F 03.223,  
P.O.Box 85500  
H.J.T.A.M. Huijbregts  
Heidelberglaan 100  
Utrecht 3508 GA  
The Netherlands  
+31 (0)30 2507379

## Eligibility criteria

### Inclusion criteria

1. Patients with chronic renal failure who require prosthetic vascular access for haemodialysis;
2. Informed consent and willing to co-operate;
3. Age 18 or older.

### Exclusion criteria

1. Inability to comply with the study follow-up;
2. Known sensitivity to ePTFE;
3. Failure to obtain written informed consent;
4. Patients who have a history of chronic bacterial infection, during the 12 months prior to potential inclusion in the study;
5. Patients with known severe coagulation disorders;
6. Inability to attend all follow up visits;

7. Patients who are on coumarin therapy;
8. Patients who are at risk of steal syndrome due to poor condition of the peripheral arterial vessels, as identified by pre-operative Duplex scan;
9. Pregnancy, intension to become pregnant.

## Study design

### Design

Study type:	Interventional
Intervention model:	Other
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

### Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	01-12-2004
Enrollment:	25
Type:	Actual

## Ethics review

Positive opinion	
Date:	12-09-2005
Application type:	First submission

## Study registrations

**Followed up by the following (possibly more current) registration**

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL393
NTR-old	NTR432
Other	: N/A
ISRCTN	ISRCTN11502523

## Study results

### Summary results

N/A